Loading…

Higher versus lower oxygenation targets in COVID‐19 patients with severe hypoxaemia (HOT‐COVID) trial: Protocol for a secondary Bayesian analysis

Background Respiratory failure is the main cause of mortality and morbidity among ICU patients with coronavirus disease 2019 (COVID‐19). In these patients, supplemental oxygen therapy is essential, but there is limited evidence the optimal target. To address this, the ongoing handling oxygenation ta...

Full description

Saved in:
Bibliographic Details
Published in:Acta anaesthesiologica Scandinavica 2022-03, Vol.66 (3), p.408-414
Main Authors: Mølgaard Nielsen, Frederik, Lass Klitgaard, Thomas, Granholm, Anders, Lange, Theis, Perner, Anders, Lilleholt Schjørring, Olav, Steen Rasmussen, Bodil
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Respiratory failure is the main cause of mortality and morbidity among ICU patients with coronavirus disease 2019 (COVID‐19). In these patients, supplemental oxygen therapy is essential, but there is limited evidence the optimal target. To address this, the ongoing handling oxygenation targets in COVID‐19 (HOT‐COVID) trial was initiated to investigate the effect of a lower oxygenation target (partial pressure of arterial oxygen (PaO2) of 8 kPa) versus a higher oxygenation target (PaO2 of 12 kPa) in the ICU on clinical outcome in patients with COVID‐19 and hypoxaemia. Methods The HOT‐COVID is planned to enrol 780 patients. This paper presents the protocol and statistical analysis plan for the conduct of a secondary Bayesian analysis of the primary outcome of HOT‐COVID being days alive without life‐support at 90 days and the secondary outcome 90‐day all‐cause mortality. Furthermore, both outcomes will be investigated for the presence heterogeneity of treatment effects based on four baseline parameters being sequential organ failure assessment score, PaO2/fraction of inspired oxygen ratio, highest dose of norepinephrine during the 24 h before randomisation, and plasma concentration of lactate at randomisation. Conclusion The results of this pre‐planned secondary Bayesian analysis will complement the primary frequentist analysis of the HOT‐COVID trial and may facilitate a more nuanced interpretation of the trial results.
ISSN:0001-5172
1399-6576
DOI:10.1111/aas.14023